Biwei Cao

1.4k total citations
34 papers, 414 citations indexed

About

Biwei Cao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Biwei Cao has authored 34 papers receiving a total of 414 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Biwei Cao's work include Brain Metastases and Treatment (3 papers), Gene expression and cancer classification (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Biwei Cao is often cited by papers focused on Brain Metastases and Treatment (3 papers), Gene expression and cancer classification (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Biwei Cao collaborates with scholars based in United States, China and Canada. Biwei Cao's co-authors include Robert B. Craven, David T. Dennis, Leonard W. Mayer, Kenneth E. Robbins, R. E. Bailey, Barbara J. B. Johnson, Xuefeng Wang, Miao Wu, Elaine Tan and Richard D. Kim and has published in prestigious journals such as Journal of Clinical Oncology, Bioinformatics and PLoS ONE.

In The Last Decade

Biwei Cao

33 papers receiving 410 citations

Peers

Biwei Cao
Biwei Cao
Citations per year, relative to Biwei Cao Biwei Cao (= 1×) peers Cynthia Yeung

Countries citing papers authored by Biwei Cao

Since Specialization
Citations

This map shows the geographic impact of Biwei Cao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Biwei Cao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Biwei Cao more than expected).

Fields of papers citing papers by Biwei Cao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Biwei Cao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Biwei Cao. The network helps show where Biwei Cao may publish in the future.

Co-authorship network of co-authors of Biwei Cao

This figure shows the co-authorship network connecting the top 25 collaborators of Biwei Cao. A scholar is included among the top collaborators of Biwei Cao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Biwei Cao. Biwei Cao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Xiaoqing, Li Song, Ling Cen, et al.. (2024). Pan-cancer γδ TCR analysis uncovers clonotype diversity and prognostic potential. Cell Reports Medicine. 5(10). 101764–101764. 2 indexed citations
2.
Cao, Biwei, Youngchul Kim, Peter Forsyth, et al.. (2024). Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review. Breast Cancer Research. 26(1). 55–55. 5 indexed citations
3.
Akhtar, Othman Salim, Biwei Cao, Xuefeng Wang, et al.. (2023). CAR T-cell therapy has comparable efficacy with autologous transplantation in older adults with DLBCL in partial response. Blood Advances. 7(19). 5937–5940. 6 indexed citations
4.
Zhou, Jing, et al.. (2023). Risk factors associated with amyotrophic lateral sclerosis based on the observational study: a systematic review and meta-analysis. Frontiers in Neuroscience. 17. 1196722–1196722. 12 indexed citations
5.
Meng, Lingbin, Biwei Cao, Rui Ji, et al.. (2023). Enhanced Efficacy of Chemotherapy by Addition of Immune Checkpoint Inhibitors in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung: A Real-World Analysis. Journal of Cancer. 14(17). 3169–3175. 3 indexed citations
6.
Patel, Krupal, Amir Alishahi Tabriz, Kea Turner, et al.. (2023). Telemedicine Adoption in an NCI-Designated Cancer Center During the COVID-19 Pandemic: A Report on Patient Experience of Care. Journal of the National Comprehensive Cancer Network. 21(5). 496–502.e6. 8 indexed citations
7.
Saglam, Ozlen, Biwei Cao, Xuefeng Wang, Gökçe Törüner, & José R. Conejo-García. (2022). Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma. PLoS ONE. 17(2). e0264014–e0264014. 2 indexed citations
8.
Cao, Biwei, et al.. (2022). A subnetwork-based framework for prioritizing and evaluating prognostic gene modules from cancer transcriptome data. iScience. 26(2). 105915–105915. 3 indexed citations
9.
Cao, Biwei, et al.. (2022). Prediction-oriented prognostic biomarker discovery with survival machine learning methods. NAR Genomics and Bioinformatics. 5(2). lqad055–lqad055. 2 indexed citations
10.
Kuznicki, Michelle, C. McClung, Biwei Cao, et al.. (2022). Prognostic features of endometrial cancer metastasis to the central nervous system. PLoS ONE. 17(8). e0268794–e0268794. 2 indexed citations
11.
Cao, Biwei, Wei Meng, Yuan Xiong, et al.. (2022). Transcriptomic analysis reveal the responses of dendritic cells to VDBP. Genes & Genomics. 44(10). 1271–1282. 3 indexed citations
12.
Cao, Biwei, et al.. (2021). Effect of baduanjin on the fall and balance function in middle-aged and elderly people. Medicine. 100(37). e27250–e27250. 8 indexed citations
13.
Li, Kaiqiao, Zhenyu Zhang, Biwei Cao, et al.. (2021). Efficient gradient boosting for prognostic biomarker discovery. Bioinformatics. 38(6). 1631–1638. 40 indexed citations
14.
Aydın, Ahmet Murat, Richard R. Reich, Biwei Cao, et al.. (2021). Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy. Urologic Oncology Seminars and Original Investigations. 40(4). 164.e1–164.e7. 1 indexed citations
15.
Figura, Nicholas, Timothy J. Robinson, Austin J. Sim, et al.. (2021). Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy. International Journal of Radiation Oncology*Biology*Physics. 111(5). 1145–1154. 28 indexed citations
16.
Tan, Elaine, Biwei Cao, Jongphil Kim, et al.. (2020). Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers. Cancer. 127(8). 1293–1300. 23 indexed citations
17.
Zhou, Jing, Biwei Cao, Xiaoya Li, et al.. (2020). Characteristic of Clinical Studies on Baduanjin during 2000–2019: A Comprehensive Review. Evidence-based Complementary and Alternative Medicine. 2020(1). 4783915–4783915. 23 indexed citations
18.
Garg, Saurabh, AGM Mostofa, Zhihua Chen, et al.. (2020). Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy. Frontiers in Immunology. 11. 164–164. 8 indexed citations
19.
Xi, Jinxiang, et al.. (2017). Multi-resolution classification of exhaled aerosol images to detect obstructive lung diseases in small airways. Computers in Biology and Medicine. 87. 57–69. 11 indexed citations
20.
Johnson, Barbara J. B., Kenneth E. Robbins, R. E. Bailey, et al.. (1996). Serodiagnosis of Lyme Disease: Accuracy of a Two-Step Approach Using a Flagella-Based ELISA and Immunoblotting. The Journal of Infectious Diseases. 174(2). 346–353. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026